Clinical Trials

  • Principal Investigator:

    Tamim M. Nazif, MD
    Are you scheduled for an interventional vascular procedure (e.g. BAV, TAVR/TAVI, EVAR or TEVAR) inorder to replace a damaged or failing valve? This research style studies the safety and efficacy of an Investigational Device (IDE) called the Cross-Seal Suture-Mediated Vascular Closure Device System. This device has not yet been approved by the FDA for use on the market. The device delivers percutaneous sutures (administers stitches through the skin) for the closure of large bores created in the common femoral artery access site during your endovascular aneurysm repair surgery. The objective of...
  • Principal Investigator:

    Mathew Maurer, MD
    A drug study looking at the effects of 10 mg Dapagliflozin vs. Placebo in patients with Heart Failure and Preserved Ejection Fraction (HFpEF) with either diabetes or pre-diabetes. Subjects are being asked to take part in this study because they have heart failure (inability of the heart to pump blood with normal efficiency). The purpose of this study is to find out if a drug called dapagliflozin would be effective in improving the blood tests and symptoms related to their heart failure. To do this, dapagliflozin will be compared with placebo. The placebo will look like dapagliflozin but will...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The early feasibility study (EFS) of the Cardioband Tricuspid System is a prospective, single arm, multi-center study to evaluate the safety and performance of the Cardioband Tricuspid System. The Edwards Cardioband Tricuspid Valve Reconstruction System is intended for patients with tricuspid regurgitation deemed to be potential candidates for transcatheter tricuspid valve reconstruction with the Edwards Cardioband Tricuspid Valve Reconstruction System by the local Heart Team.
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The study is designed to to compare the safety and effectiveness of the PASCAL System to the MitraClip System for reduction of degenerative mitral regurgitation.
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The study is to determine whether aortic valve replacement is helpful for patients who have severe, calcific, aortic stenosis (a narrowing of the aortic heart valve, where calcium has attached to the valve surface, resulting in obstructed blood flow) and do not have symptoms.
  • Principal Investigator:

    Robert J. Sommer, MD
    This study will evaluate Patent Foramen Ovale (PFO) closure for migraine headache relief using a device called the GORE CARDIOFORM Septal Occluder. A patent foramen ovale (PFO) is a hole in the heart that didn't close the way it should after birth. During fetal development, a small flap-like opening the foramen ovale is normally present in the wall between the right and left upper chambers of the heart (atria). Most patients with a PFO do not have any symptoms. However, the condition may play a role in migraine headaches and it increases the risk of stroke, transient ischemic attack (stroke...
  • Principal Investigator:

    Ajay J. Kirtane, MD, SM
    This study has been designed to treat patient with coronary artery disease and demonstrate the superiority of the OCT device used to select and guide the stenting procedure when collecting images and flow measures inside the blocked artery.
  • Principal Investigator:

    Sanjum Sethi, MD
    This is a prospective, multi-center, observational, post-market study that will evaluate the safety and procedural success of performing transradial access for treatment of atherosclerotic lesions in the lower extremities. This research study will collect outcome data of patients undergoing percutaneous endovascular treatment of Peripheral Artery Disease (PAD) in the lower extremities via radial artery access. Additionally, the complication rates and patient satisfaction in these patients who are having a standard procedure for PAD will be assessed.
  • Principal Investigator:

    Tamim M. Nazif, MD
    The objective of this study is to collect outcome data on valve performance and a pre-specified TAVR care pathway. Transcatheter aortic valve replacement (TAVR) has been shown to be a safe and effective treatment for patients with severe aortic stenosis who are at extreme, high, or intermediate surgical risk. Since CoreValveTM became commercially approved in the United States by the Food and Drug Administration (FDA) in 2014, the procedure and valve iterations have become increasingly efficient with reducing complications. The EvolutTM PRO valves outer pericardial wrap has shown to enhance...
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    The study is assessing the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

Pages